Odanacatib
Odanacatib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against cathepsin K. In addition, it is known to target cathepsin Z and cathepsin S.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 6 | 3 | 5 | — | — | 14 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | 1 | 2 | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bone diseases | D001847 | — | M89.9 | — | 1 | — | — | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Odanacatib |
| INN | odanacatib |
| Description | Odanacatib (INN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.
|
| Classification | Small molecule |
| Drug class | cathespin inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 603139-12-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL481611 |
| ChEBI ID | — |
| PubChem CID | 10152654 |
| DrugBank | — |
| UNII ID | N673F6W2VH (ChemIDplus, GSRS) |
Target
Alternate
CTSZ
CTSZ
CTSS
CTSS
Organism
Homo sapiens
Gene name
CTSZ
Gene synonyms
NCBI Gene ID
Protein name
cathepsin Z
Protein synonyms
carboxypeptidase LB, cathepsin B2, cathepsin IV, Cathepsin P, Cathepsin X, cathepsin Y, cathepsin Z1, cysteine-type carboxypeptidase, lysosomal carboxypeptidase B, preprocathepsin P
Uniprot ID
Mouse ortholog
Ctsz (64138)
cathepsin Z (Q9WUU7)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 863 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use